Treatment of Breast Cancer Cells by IGF1R Tyrosine Kinase Inhibitor Combined with Conventional Systemic Drugs
Anticancer Research,

Hartog H et al. – Antagonistic effects should be anticipated when IGF1R inhibitors are combined with conventional systemic drugs in a subset of breast tumors. Development of functional biomarkers predicting tumor response to tailored insulin–like growth factor–1 receptor (IGF1R) therapy is warranted.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Obstetrics & Gynecology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Obstetrics & Gynecology Articles

Indexed Journals in Obstetrics & Gynecology: Obstetrics and Gynecology, American Journal of Obstetrics and Gynecologymore